Latest Metformin Stories
--Microbiome Modulator NM504 Significantly Improved Blood Glucose Control and Other Metabolic Parameters in Patients with Prediabetes and Type 2 Diabetes-- CHICAGO and BROOMFIELD,
- Recent Publication Shows Metformin Improves Glycemic Control by Modulating the Gut Microbiome and Triggering Specific Cellular and Immune Mechanisms - BROOMFIELD, Colo., June
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc analysis showing that patients with type 2 diabetes having treatment intensified with insulin glargine therapy while also being treated with JANUVIA® (sitagliptin) 100 mg once-daily had a lower incidence of nighttime (nocturnal) hypoglycemia compared to patients also receiving placebo.
-- In a two-year study, empagliflozin as add-on to metformin demonstrated significantly greater decreases in A1C (blood glucose), body weight and blood pressure compared with glimepiride as add-on
Up to 2.25 percentage point reduction in HbA1c achieved after only 13 weeks of dosing CARLSBAD, Calif., June 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
African Americans taking the diabetes drug metformin saw greater improvements in their blood sugar control than white individuals who were prescribed the same medication.
ROCKVILLE, Md., June 10, 2014 /PRNewswire-USNewswire/ -- Patients with type 2 diabetes who take a combination of metformin plus insulin may be at higher risk for cardiovascular disease and death
Traditional Type 2 Diabetes Drug Attributes Continue to be Key Even as First-Line Treatment Paradigms Shift, According to Findings from Decision Resources Group BURLINGTON,
ORMD-0801 Oral Insulin Appeared Safe and Well-tolerated.
Avail is conducting a 6-week, Phase 2 randomized study to assess the safety, tolerability and pharmacodynamics of a new combination therapy administered to
- Large; stout; burly.